API | abediterol

abediterol Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Abediterol is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials. ^Wikipedia

Chemistry

SMILES: O[C@@H](CNCCCCCCOCC(F)(F)c1ccccc1)c2ccc(O)c3NC(=O)C=Cc23
InChIKey: SFYAXIFVXBKRPK-QFIPXVFZSA-N
Mol. Mass: 460.52
ALogP: 4.23 Partition coefficient
ChEMBL Molecule:
abediterol

More Chemistry

Pharmacology

Mechanism of Action:
- Beta-2 adrenergic receptor (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

5-(2-((6-(2,2-difluoro-2-phenylethoxy)hexyl)amino)-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one | abediterol | las100977 | las-100977

Organizations (3)

Research & Development (3)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (2)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (2)

Asthma (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 6
# of Trial Organizations: 3

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue